Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis
Abstract The treatment strategy for management of Burkitt lymphoma (BL) has evolved during the past decades and the clinical outcome for this disease as a whole has also improved. Due to limited information reported on survival trends of patients with stage I/II (limited‐stage) BL, here we used the...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.1870 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576236937805824 |
|---|---|
| author | Ze‐Long Liu Pan‐Pan Liu Xi‐Wen Bi De‐Xin Lei Yu Wang Zhi‐Ming Li Wen‐Qi Jiang Yi Xia |
| author_facet | Ze‐Long Liu Pan‐Pan Liu Xi‐Wen Bi De‐Xin Lei Yu Wang Zhi‐Ming Li Wen‐Qi Jiang Yi Xia |
| author_sort | Ze‐Long Liu |
| collection | DOAJ |
| description | Abstract The treatment strategy for management of Burkitt lymphoma (BL) has evolved during the past decades and the clinical outcome for this disease as a whole has also improved. Due to limited information reported on survival trends of patients with stage I/II (limited‐stage) BL, here we used the Surveillance, Epidemiology, and End Results (SEER) database to conduct our study. The time period was divided into two eras (1983‐2001 and 2002‐2014) as the recent era reflected more intensive chemotherapy regimens, the availability of rituximab, the widespread use of antiretroviral therapy (ART) and improvements in supportive care. Patients with limited‐stage BL had a significantly better 5‐year overall survival (OS) in the 2002‐2014 era in both univariate analysis and multivariate analysis, compared with those in the 1983‐2001 era (64.1% vs 57.4%). However, clinical outcomes of elderly patients (≥60 years) and children patients (0‐19 years) did not significantly improve. Older age and race of black were correlated with poorer OS in multivariate analysis, whereas sex, primary sites, and application of radiotherapy did not significantly influence OS. In conclusion, the prognosis of patients with limited‐stage BL has improved in the 2002‐2014 era, but the outcome was still much poorer in elderly patients, which needs to be improved by identifying newly molecular‐targeted drugs and developing novel personalized therapeutic approaches. |
| format | Article |
| id | doaj-art-e3cbf8e08e344538bc158ca844931e2d |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2019-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-e3cbf8e08e344538bc158ca844931e2d2025-01-31T08:47:42ZengWileyCancer Medicine2045-76342019-03-018387488110.1002/cam4.1870Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysisZe‐Long Liu0Pan‐Pan Liu1Xi‐Wen Bi2De‐Xin Lei3Yu Wang4Zhi‐Ming Li5Wen‐Qi Jiang6Yi Xia7Department of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou People’s Republic of ChinaDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou People’s Republic of ChinaDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou People’s Republic of ChinaDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou People’s Republic of ChinaDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou People’s Republic of ChinaDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou People’s Republic of ChinaDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou People’s Republic of ChinaDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Centre of Cancer Medicine Sun Yat‐sen University Cancer Center Guangzhou People’s Republic of ChinaAbstract The treatment strategy for management of Burkitt lymphoma (BL) has evolved during the past decades and the clinical outcome for this disease as a whole has also improved. Due to limited information reported on survival trends of patients with stage I/II (limited‐stage) BL, here we used the Surveillance, Epidemiology, and End Results (SEER) database to conduct our study. The time period was divided into two eras (1983‐2001 and 2002‐2014) as the recent era reflected more intensive chemotherapy regimens, the availability of rituximab, the widespread use of antiretroviral therapy (ART) and improvements in supportive care. Patients with limited‐stage BL had a significantly better 5‐year overall survival (OS) in the 2002‐2014 era in both univariate analysis and multivariate analysis, compared with those in the 1983‐2001 era (64.1% vs 57.4%). However, clinical outcomes of elderly patients (≥60 years) and children patients (0‐19 years) did not significantly improve. Older age and race of black were correlated with poorer OS in multivariate analysis, whereas sex, primary sites, and application of radiotherapy did not significantly influence OS. In conclusion, the prognosis of patients with limited‐stage BL has improved in the 2002‐2014 era, but the outcome was still much poorer in elderly patients, which needs to be improved by identifying newly molecular‐targeted drugs and developing novel personalized therapeutic approaches.https://doi.org/10.1002/cam4.1870Burkitt lymphomarituximabSEER analysissurvival |
| spellingShingle | Ze‐Long Liu Pan‐Pan Liu Xi‐Wen Bi De‐Xin Lei Yu Wang Zhi‐Ming Li Wen‐Qi Jiang Yi Xia Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis Cancer Medicine Burkitt lymphoma rituximab SEER analysis survival |
| title | Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis |
| title_full | Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis |
| title_fullStr | Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis |
| title_full_unstemmed | Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis |
| title_short | Trends in survival of patients with stage I/II Burkitt lymphoma in the United States: A SEER database analysis |
| title_sort | trends in survival of patients with stage i ii burkitt lymphoma in the united states a seer database analysis |
| topic | Burkitt lymphoma rituximab SEER analysis survival |
| url | https://doi.org/10.1002/cam4.1870 |
| work_keys_str_mv | AT zelongliu trendsinsurvivalofpatientswithstageiiiburkittlymphomaintheunitedstatesaseerdatabaseanalysis AT panpanliu trendsinsurvivalofpatientswithstageiiiburkittlymphomaintheunitedstatesaseerdatabaseanalysis AT xiwenbi trendsinsurvivalofpatientswithstageiiiburkittlymphomaintheunitedstatesaseerdatabaseanalysis AT dexinlei trendsinsurvivalofpatientswithstageiiiburkittlymphomaintheunitedstatesaseerdatabaseanalysis AT yuwang trendsinsurvivalofpatientswithstageiiiburkittlymphomaintheunitedstatesaseerdatabaseanalysis AT zhimingli trendsinsurvivalofpatientswithstageiiiburkittlymphomaintheunitedstatesaseerdatabaseanalysis AT wenqijiang trendsinsurvivalofpatientswithstageiiiburkittlymphomaintheunitedstatesaseerdatabaseanalysis AT yixia trendsinsurvivalofpatientswithstageiiiburkittlymphomaintheunitedstatesaseerdatabaseanalysis |